AdAlta Limited (ASX:1AD)

Australia flag Australia · Delayed Price · Currency is AUD
0.0050
+0.0010 (25.00%)
Apr 29, 2026, 3:58 PM AEST
0.00%
Market Cap 12.75M
Revenue (ttm) 608.07K
Net Income (ttm) -4.36M
Shares Out 2.55B
EPS (ttm) -0.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 32,980,605
Average Volume 6,003,185
Open 0.0050
Previous Close 0.0040
Day's Range 0.0050 - 0.0060
52-Week Range 0.0020 - 0.0080
Beta 0.03
RSI 71.42
Earnings Date May 20, 2026

About AdAlta

AdAlta Limited, a clinical-stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia. Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including idiopathic pulmonary fibrosis, eye fibrosis, and fibrosis diseases of the liver, skin and kidney, as well as for the treatment of age-related macular degeneration. It has discovered WD-34 for the multiple malaria species, Babesia, and Toxoplasma in collaboration with La Trobe Univers... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 1
Stock Exchange Australian Securities Exchange
Ticker Symbol 1AD
Full Company Profile

Financial Performance

In fiscal year 2025, AdAlta's revenue was 677,010, a decrease of -61.04% compared to the previous year's 1.74 million. Losses were -4.50 million, -16.33% less than in 2024.

Financial Statements

News

There is no news available yet.